MedPath

FDA Advisory Committee Skeptical of Stealth BioTherapeutics' Barth Syndrome Drug Application

• Stealth BioTherapeutics faced scrutiny from the FDA's Cardiovascular and Renal Drugs Advisory Committee regarding its drug application for Barth syndrome. • Committee members questioned the feasibility of conducting a new randomized trial, citing challenges like potential functional unblinding. • Despite concerns, the committee acknowledged that inherent difficulties could compromise the integrity of a new study. • The advisory committee's skepticism raises uncertainty about the potential approval of Stealth BioTherapeutics' drug for Barth syndrome.

Stealth BioTherapeutics encountered significant skepticism from the FDA's Cardiovascular and Renal Drugs Advisory Committee concerning its application for a new drug intended to treat Barth syndrome. The committee members repeatedly challenged Stealth's assertion that a new randomized trial in Barth syndrome was not possible.

Concerns Over Trial Feasibility

The advisory committee voiced concerns about the feasibility of conducting a new randomized trial. Members pointed out potential functional unblinding and other challenges that could compromise the integrity of a new study. Functional unblinding occurs when patients or investigators can deduce the treatment assignment based on observed effects, potentially biasing the results.

Impact on Approval Prospects

The skepticism from the advisory committee introduces uncertainty regarding the potential approval of Stealth BioTherapeutics' drug. While acknowledging the difficulties inherent in studying rare conditions like Barth syndrome, the committee's reservations highlight the need for robust evidence to support drug efficacy and safety. The FDA will consider the advisory committee's feedback when making its final decision on the drug application.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cysteamine Ophthalmic Solution Shows Promise in Japanese Cystinosis Patients

A Phase III study in Japan evaluated cysteamine hydrochloride 0.55% ophthalmic solution for treating corneal cystine crystals in cystinosis patients.
The study showed a decrease in corneal crystal density and improvement in photophobia, suggesting potential efficacy in Japanese patients.

FDA Raises Doubts About Stealth BioTherapeutics' Elamipretide for Barth Syndrome

The FDA has expressed significant concerns regarding the effectiveness of Stealth BioTherapeutics' elamipretide for treating Barth syndrome.
According to the FDA, the drug failed to meet its primary endpoints in the pivotal TAZPOWER trial, raising questions about its efficacy.

FDA Advisory Committee Backs Elamipretide for Barth Syndrome Despite Data Concerns

The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in favor of elamipretide for treating Barth syndrome, a rare genetic disorder.
The decision was made despite concerns about the strength and design of the clinical trial data presented by Stealth BioTherapeutics.

FDA Advisory Committee to Review Rare Disease Treatment Amid Efficacy Concerns

An FDA advisory committee will convene to evaluate a rare disease drug, a decision influenced by strong advocacy from patient communities.
The FDA has expressed concerns regarding the treatment's efficacy, highlighting the challenges of conducting trials for rare diseases with limited patient populations.

FDA Panel Rejects Ocaliva's Full Approval for Primary Biliary Cholangitis

An FDA advisory committee voted against full approval of obeticholic acid (Ocaliva) for primary biliary cholangitis (PBC) due to insufficient evidence of clinical benefit.
The COBALT trial, intended to confirm Ocaliva's efficacy, failed to demonstrate a significant reduction in liver transplantation, death, or liver-related outcomes.

FDA Advisory Committee Recommends Narrowing Sulopenem's Indication for UTI Treatment

FDA advisory committee suggests limiting sulopenem's use to patients with specific complicated urinary tract infections (cUTIs) where alternative treatments are limited.
The Antimicrobial Drugs Advisory Committee voted that the benefits of sulopenem outweigh the risks, but only for a restricted patient population.

FDA Advisory Committee to Review Elamipretide for Barth Syndrome

The FDA's Cardiovascular and Renal Drugs Advisory Committee will review elamipretide for Barth syndrome on October 10, 2024.
Elamipretide, a first-in-class mitochondria-targeted therapeutic, is under review as a potential treatment for this ultra-rare genetic condition.

FDA Accepts Stealth BioTherapeutics' NDA for Elamipretide in Barth Syndrome

The FDA has accepted Stealth BioTherapeutics' NDA for elamipretide, a potential first-in-class therapy for Barth syndrome, a rare genetic condition.
The NDA is supported by positive data from the SPIBA-001 Phase 3 study and the TAZPOWER Part 2 trial, highlighting elamipretide's efficacy and safety.

FDA Accepts Elamipretide NDA for Barth Syndrome Treatment

The FDA has accepted Stealth BioTherapeutics' NDA for elamipretide in treating Barth syndrome, a rare genetic condition with no approved therapies.
The application is supported by Phase 3 data and additional efficacy/safety data, with the FDA planning an advisory committee meeting for review.

Reappraisal of US Clinical Trials on Post-Treatment Lyme Disease Syndrome

Two out of four U.S. treatment trials demonstrated the efficacy of IV ceftriaxone on primary and/or secondary outcome measures for post-treatment Lyme fatigue.
Treatment guidelines should clarify that IV ceftriaxone for post-treatment Lyme fatigue was demonstrated effective in one RCT and supported by a second RCT.

Reference News

[1]
US Advisory Committees | Pink Sheet - Citeline
insights.citeline.com · Oct 16, 2024

Cardiovascular and Renal Drugs Advisory Committee questioned Stealth’s claim that a new randomized trial in Barth syndro...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy